Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Dransfield
Paul Dransfield, San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090111859 | Substituted biphenyl GPR40 modulators - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: | 04-30-2009 |
| 20100075974 | HETEROCYCLIC GPR40 MODULATORS - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: | 03-25-2010 |
| 20100137323 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: | 06-03-2010 |
Paul J. Dransfield, San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100298367 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: | 11-25-2010 |
Paul John Dransfield, San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090137561 | Substituted biphenyl GPR40 modulators - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: | 05-28-2009 |
| 20100331293 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 12-30-2010 |